Member Info for dactions

I have to wonder why the products came off Amazon in the first place, the MD having decided to give that market a try in the first place ?
Answering my own question, they were in a hurry to make up for the obvious delay in getting them manufactured. Something was badly wrong at the Genome Store - presumably the products didn't work under early tests - which is why MHC didn't honour the incentive bonus of £1 million in shares when they were originally acquired. But then we have to accept that the DNA test have not been selling. Apart from one spurious review mid-summer, we have seen no other reviews on TrustPilot nor on Amazon, the latter business encourages buyers to review good or bad. If my analysis is correct, so why put them back now ?

Again, answering my own question, my thoughts are that they are not selling from their extensive database of Covid customers either. I've received numerous marketing emails from the Company on each of the products. They're all attractive but but there's never been any marketing inducement - either outright promotional discount, or a softer one, say 'buy two, save x % - nor has they're been any publicity, product placing, newspaper reviews etc. that I've seen. I'm accepting that they haven't agreed a tie-up with say Boots because there is insufficient margin at the product price £45 + VAT to absorb the high take that Boots would want. If there is a positive in all this, it is my firm belief that Penny watches the pennies which is a good thing - but we do have cash in the Bank (or did) and now's the time to get these new products working - assuming that is the knowledge a customer would learn from taking up a test is truly worthwhile.

Penny clearly concluded her September statement:
"I want to thank each person who has delivered for MHC this year, doing so alongside the work being undertaken as we work towards a new portfolio and associated launches, which we are excited to share with the market in Q4."
In my view they have insufficient personnel to develop the products or manage the publicity of what they do have - look at TrustPilot, the reviews have all but dried up - in the last 10 which span back to early November, 3 were absolutely dreadful.

Penny mentioned something more exciting in that September statement:
"Development technology builds for new blood testing launch in Q4 2022"
I reckon this would be quite an advance allowing a whole host of new products and from my amateurish knowledge (based partly on seeing what Randox are doing) would offer MHC much better margins. If all this work is falling on just Penny and the Financial director's shoulders, then this would definitely explain the lack of promised updates.

We can't kid ourselves about the lack of market support for the shares when Company news has been lacking. Finally, could the current malaise at YourGene be impacting on us ? All in all, it's hard to know.
GLA

Crazyyear - as a very LTH, I'm definitely positive as to FUM's future but after reading your comments, I'm even more so.

I have to be honest and say, I hadn't seen all the detail you mention before. It looks like I've been a bit lax in my own ongoing research - thankfully it's all positive though.
Cheers Crazyyear.

It is not actually a binary choice as much depends upon other triggers such as Cooper announcing UK manufacture/sales - but going along with the question:

80p plus:
With FDA approval for over the counter sales - it will bounce to 80p within 2 or 3 days trading especially if it's announced early in the week. If that were the case, I could see it breaking £1 by the weekend but would expect it to pull back in the following week.

45p - 65p:
I don't see how the FDA can decline to allow OTC sales, given the cautious steps FUM has followed with the FDA over the past year. However, we know lobbying by interested parties is rife and there may be some form of words delaying OTC sales. That would hurt the SP in ways we cannot be sure but if it were matched by FUM announcing actual production in Europe/UK, then I don't foresee a calamity with the SP at all - we could in fact see a rise in this case too.

Quite agree Dosanddonts - Zwartkops is simply hoping to trade this as he's done in the past.

I’m disappointed there has been no update - and I take that as a negative that the new products are not performing. I haven’t seen any publicity and/or press placings and if that’s right and not just me saying it, then in my opinion that would account for low take-up.

However, at the current sp one can only wait and hope the Board recognise the need for publicity.

Interesting thoughts - soonbetime.
The sp prior to the covid awareness in early spring 2020 had been bumping along at around lows of 8p and had been languishing for a long time as I recall. We seem to be heading that way and the major difference this time is that the company’s pay bill is whoppingly higher.

Something has to change this time and a Polygon move seems a more likely scenario.

Whatever happens - all best wishes to everyone.

BruceJamieson - I did read your earlier comment and have noted your many comments which are usually one-liners which are easily prone to be misinterpreted. Viagra has been out of patent for 2 years and being such old news, I thought your point was that production by others could flood the market with viagra lookalikes - sorry for misinterpreting you.

But I'll raise you on your pithy comment "I think we can expect a 3 bagger" and make it a 4 bagger sometime in 2023.
Good luck all.

What's your point Bruce - are you trying to put a damper on FUM once again ?

81lucky - if you’re implying that even if the FDA prove troublesome with their final approval the Board could still mage to succeed with the rest of the world contracts, I agree with you.

As we have respected Cooper already on board ready for the large European market, then I can see FUM can still go on to good things in the next quarter.

I’ve come to realise, that it is now a win/win share - it’s just a matter of how much the sp will benefit - will it be good or will it be even better ?

With the change of name, trading ID and shortly to come consolidation of 100 shares to 1 next week, can we expect a turning point here at Falanx ? The Chairman's report put a positive spin on recent trading but is it 'spin' ?

As a LTH, I've seen numerous statements from CEO Mike Read foretelling good news just round the corner and added around .07p mark to my long-term holding bought at much higher rates substantially improving my buying average. Earlier this year there were sizeable buys from the Board at 1p - 1.25p - quite a substantial percentage difference. Now, following a consolidation, the shares could see more selling. I've seen with other consolidations, prior to the consolidation taking effect there is effectively no realistic market as the spread becomes too wide - this has clearly been the case with Falanx. Following other consolidations, I can think of RENE or VOG two cases which immediately come to mind, trades become available again and large holders have used it as their exit point at the expense of small holders.

Is this now a turning point for Falanx ?
For the good at last ?
Or more failure ?

I'm a very long term holder in Futura and seen the price gyrate to 90p down to 6p I recall - over the years one could have traded this very profitably as it swung back and forth, never quite holding on to its peaks for any decent period and to some extent never lingered too long in the troughs either. I recall the Daily Mail article 9th September 2016 headlined: "Viagra too slow for you ? Now for the gel that works in 5 mins" and the implication was a market launch in less than 2 years.

Here we are over 6 years later and we're teasingly told that sales can be expected later 1st half 2023.
Slowly, slowly the publicity machine is being geared up with the briefest of details as to contracts signed, manufacturing dates as James Barder says that can't say too much because of commercial sensitivities ! It seems to me that the BoD has decided all must wait on the FDA final approval to allow over the counter sales in the US. Too many positives have already been released about the work done on submitting 'full dossiers' to the FDA, about the conformity of meeting all of its requirements to counteract any likelihood of now not being approved by the FDA.

We were told that the European/UK contract assigned to Coopers was only agreed after they had satisfied themselves fully that the product actually worked to their satisfaction.

The sp has now moved back to a place I believe will stabilise awhile before moving slowly ever more forward. When the RNS is announced that the final approval from the FDA is given probably within the next 2 to 3 months, I feel sure that the sp could bust the £1 barrier and much will depend on the Board's management of publicity as to how far it will go upwards even before any sales take place.

Another Daily Mail headline like 2016 and anything is possible. And if the sales progress worldwide - I foresee they will self-generate from country to country as publicity feeds upon itself. At that point there will have been a hefty increase in the sp and shareholders can decide whether to take profits risk-free, or stay the course if they believe the product really is the gem that the two ED specialists appear to describe it - thanks to the link above from 'wearelallguessing'

https://www.futuramedical.com/investor-centre/videos-and-webcasts/videos/

Here's James Barder 's Proactive interview this morning just released. Looking for some new news - as The.Italian queried above in the previous post - at least Barder is smiling more this time :)

https://www.youtube.com/watch?v=AZ1uLC9XxPI

Today's RNS is mostly already well-known by us shareholders, but today's message has been dressed up well. I don't expect much further news until February - I don't know what others think. But it should keep the sp stable until then. Here's Proactive's take on the news:

https://www.proactiveinvestors.co.uk/companies/news/1001025/futura-medical-hails-progress-of-med3000-gel-1001025.html

Bringing this post to the fore- difficult ride at the moment for long term holders but will be worth sitting on hands.

Next Update critical - i wouldn't agree Ambers235 - unless you mean for us shareholders wellbeing - ie to get the sp where it should be - which in my opinion is above 3p.

You're right about their absence from Amazon - I hadn't spotted that. Whilst the margin loss from an Amazon sale is peanuts, that from a Boots or Lloyd is likely to be around 30 - 40%. Given that the current sale price is £45 + vat is not going to leave a lot to package/service the products but to my mind is the only way these products are going to sell. If they're as good as they think they are, MHC can afford a higher margin loss to get them off the ground initially.

Trustpilot reviews are now very low indeed and without volume, the % of bad to good reviewers is bound to go up and that will not look very good - take a look now and the negatives hit you in your face. Perhaps you're right Ambers235 - the Amazon change could suggest a retail link-up in the offing. I did get a marketing email a week back encouraging me to take up the Heart test but I'd sooner they got on with a retail move pronto.

I still have my holding in FLX and it's been years that they've promised jam tomorrow.

When will they learn that it's results that are needed - cut your costs until you can afford them (ie make a profit). I sense that at last they are closer to a profit position but consolidating the shares isn't the way forward. Better they die now rather than kid yet more backers that all will be well and then watch a 100 x shareprice dilute. As it stands right now, at sub 1p, they have all the impetus they need to perform.

Consolidate now and all that will happen is that they will be tempted to just sell more shares and/or borrow. Without the Company getting to grips with staff/management performance - it'll be a cop-out and end up with yet more shareholders dilution.

Great news HawaiifiveO - but I'm at a loss to know why the likes of Lombard Odier and Miles Pelham have been running down their holdings in recent weeks at such a low sp. Especially given that Woodbois' trading numbers continue to grow positively and the company is held in such high esteem with the President and senior cabinet ministers of Gabon.

Woodbois is supporting Gabon at the COP27 both promoting Carbon Credits for the country - and is making a start for itself too in a small way in this market.

It's one of those times when as a Private Investor, you can't do much but watch and be patient. Their current financial numbers are very good and trading forecasts continue on an upward trend - and if that wasn't enough, there is the Carbon Credits potential. GLA

For what it's worth, I met who I perceive to have excellent knowledge of the Company - I've mentioned this in the past - I can only say that they said 'stick with it'. Trouble is they don't see it as we do - an sp seemingly without friends - they see it as the Company is doing well.

So, for what it's worth, the message is: 'stick with it'.

Mornington-oz - I totally agree that the potential at Woodbois is huge - but for whatever reason Lombard Odier is downsizing it's holding and I'm assuming we'll have another TRN-1 shortly showing their new lower holdings.

The numbers from Woodboisr 3rd quarter trading were excellent and all the more so against the current world back-drop - I can only assume LO are raising funds for alternative investments given how widely is the current investing malaise which often throws up investing opportunities where shares have been oversold.

I would say though that Woodbois looks just like such an oversold share and/or investment opportunity ! For the time being though, I'm going to have to sit on my hands and be patient.

It was definitely £2000 for a course of treatment.

That number I heard him say when I was at an early share investors meeting probably around 2016/2017. Might have been in Westminster Hall when the big Investor Show was put on by Tom Winnifrith. Also, I think it is mentioned in the youtube that we all saw on this BB in 2020 when he used that number to show how the company would be worth x billions to a big Pharma.